There are no standard criteria for the diagnosis of chemotherapy-induced peripheral neuropathy

According to a review published in The Ocular Surface, clinicians need to develop a standardized approach to detecting and monitoring eye changes caused by chemotherapy-induced peripheral neuropathy (CIPN). Once these markers are defined, they can be observed and monitored by in vivo confocal microscopy of the cornea.

Neurotoxic cancer drugs have been linked to peripheral nerve damage and neuropathic changes to the surface of the eye, particularly the cornea. Investigators examined peer-reviewed articles, including original studies and published case reports, published between January 2000 and May 2021. They found that there is no standardized protocol for diagnosing CIPN because there is no reliable, objective method of structurally observing nerve damage.

To mitigate the effects of CIPN patients, the first step is to develop an agreed, standardized approach to define the key changes to look for and monitor. Researchers can then explore the benefits of using in vivo confocal corneal microscopy to monitor the development and progression of CIPN.

Continue reading

“Other gaps in knowledge and issues that should be addressed with neurotoxic chemotherapy and CIPN related to neuropathic changes include other potential changes in the subbasal corneal nerve plexus, such as corneal dendritic cells, microneuromas and tortuosity,” the research adds.


Chiang JCB, Goldstein D., Park SB, et al. Changes in the corneal nerve after treatment with neurotoxic cancer drugs. Ocul surf. 2021; 21 (6): 221-237. doi: 10.1016 / j.jtos.2021.06.007

This article originally appeared on Ophthalmology Advisor


Cancer Diagnostic Tests General Ophthalmology Neuropathy Pain

Related Articles